poisar

Stocks · News reference

Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary Retention

Jul 16, 2026, 11:33 AMBenzinga Newsdesk

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MDCX
Source
benzinga
Observed
Jul 16, 2026, 11:33 AM
Checked
Jul 16, 2026, 11:33 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jul 31, 2026, 11:30 AMNa

    Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

    Medicus Pharma Ltd. announced that the UAE Department of Health has granted IND authorization for its PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe endometriosis. The prospective genomics-guided precision medicine study will enroll approximately 84 women across multiple sites in the UAE and aims to identify biomarkers predicting treatment response to the long-acting GnRH antagonist.

    Read original at globenewswire-inc
    MDCXMDCXW